Toluene ? associated myelofibrosis

Bosch, Xavier; Jm, Campistol; Montolíu, J; Cervantes, Francisco; Revert, L

doi:10.1007/bf00320778

Cited by 8 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is an uncommon disease, with a reported annual incidence of around 0.4 per 100,000 population [4, 5], with the highest rates being documented among Ashkenazi Jews in northern Israel [6]. The disease’s aetiology remains largely unknown, although environmental factors may be relevant in a minority of patients, in view of the reported links with radiation [7, 8], as well as benzene and toluene exposure [9, 10, 11]. With reported median survivals ranging from 3 to 5 years, idiopathic myelofibrosis has the worst outcome among the chronic myeloproliferative disorders [12].…”

Section: Introductionmentioning

confidence: 99%

Cytogenetic and Molecular Genetic Aspects of Idiopathic Myelofibrosis

Reilly

2002

Acta Haematol

View full text Add to dashboard Cite

Idiopathic myelofibrosis is a chronic myeloproliferative disorder in which the characteristic fibroblast proliferation is thought to be a secondary phenomenon resulting from the inappropriate release of megakaryocyte- and/or monocyte-derived growth factors, including PDGF, TGF-β, bFGF and calmodulin. In contrast, the haematopoietic cells are clonal, although the underlying pathogenetic mechanisms remain essentially unknown. Cytogenetic studies have highlighted that 13q–, 20q–, +8 and abnormalities of chromosomes 1, 7 and 9 constitute more than 80% of the chromosomal changes. A third of idiopathic myelofibrosis cases have abnormal karyotypes at diagnosis, a figure that increases if follow-up analyses are performed. Evolution to more complex karyotypes may accompany clinical progression, with abnormalities increasing to around 90% following acute leukaemic transformation. Cytogenetic abnormalities have been associated with prognosis and to a lack of treatment response to androgens. Oncogene mutations are rare and include point mutations in N-RAS, c-KIT and TP53.

show abstract

Section: Introductionmentioning

confidence: 99%

Cytogenetic and Molecular Genetic Aspects of Idiopathic Myelofibrosis

Reilly

2002

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…A study that was conducted in the USA has shown that the ratio is 1.83 [11]. Obviously, the prevalence in males is higher and this could be explained by the high exposure to benzene and toluene which are well known to be causative agents for myelofibrosis [12], [13], [14]. Toluene and benzene are natural ingredients of crude oil and gasoline [15].…”

Section: Discussionmentioning

confidence: 99%

The Prevalence of Myeloproliferative Disorders in A Group of Iraqi Patients And Its Relation To Blood Indices Parameters

Abdulnabi

Al-Saadi

2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

AIM: The aim of this study was to measure the prevalence of myeloproliferative disorders in a sample of Iraqi patients and to measure the changes in patients’ blood parameters. BACKGROUND: Myeloproliferative disorders are a group of neoplasms affecting the bone marrow progenitor cells characterized by excess cells with a risk of transforming to acute leukemia. There is a gap in knowledge about the prevalence of Iraqi population. Thus, we investigated the prevalence and distribution of different types of myeloproliferative disorders in a sample of Iraqi patients. MATERIALS AND METHODS: Cross-sectional study is done at the National Center of Hematology from November 2019 till March 2020 on 75 patients who were diagnosed by a specialist hematopathologist to have one subtype of myeloproliferative disorders (MPDs). Blood samples were taken from them and analyzed to get complete blood count, blood film, bone marrow aspirate, and biopsy that were analyzed for each patient. Blood samples were taken from them and analyzed in terms of blood indices, which include red blood cells, white blood cells, and platelets. RESULTS: The 75 patients were found to be comprising 35 chronic myelogenous leukemia (CML) patients (46.7%), myelofibrosis 22 patients (29.3%), essential thrombocythemia (ET) 9 patients (12%), and polycythemia vera (PV) 9 patients (12%). In terms of male/female ratios, they were as follows: Myeloproliferative neoplasms (MPNs) male-to-female ratio is 1.2, CML= 0.94, myelofibrosis= 2.14 and ET= 0.5 and PV male-to-female ratio is 2. CONCLUSIONS : MPN male-to-female ratio in Iraq, which is 1.2, CML is the most common subtype. Regarding myelofibrosis, in our study, the male-to-female ratio is 2.14, which is much higher other countries. This could be attributed to high exposure to benzene and toluene which are well known to be causative agents for myelofibrosis. Regarding ET or PV, the male-to-female ratios were compatible with other countries.

show abstract

“…Although the etiology of MF is unknown, its development has been linked to ionizing radiation (eg, in atomic bomb survivors) and benzene or toluene exposure. [21][22][23][24][25] Current understanding suggests that MF occurs secondary to acquired mutations that target the hematopoietic stem cell. 1 As a result, ineffective hematopoiesis and proliferation of dysfunctional megakaryocytes are commonly seen in MF.…”

Section: Pathophysiologymentioning

confidence: 99%

Advances in the Management of Myelofibrosis

et al. 2012

View full text Add to dashboard Cite

Significant advances have been made in understanding the pathophysiology of MF, leading to novel therapeutic approaches. The discovery of the JAK2 mutation and the development of JAK2 inhibitors provide clinicians with a new effective treatment option. Ruxolitinib is the first JAK1/2 inhibitor approved by the Food and Drug Administration (FDA) for the treatment of patients with intermediate- or high-risk MF. In clinical studies, ruxolitinib produced a significantly greater reduction in spleen size and improved quality of life compared with placebo or best available therapy. Several future therapies, including combination therapies with ruxolitinib, are currently under investigation.

show abstract

Toluene ? associated myelofibrosis

Cited by 8 publications

References 5 publications

Cytogenetic and Molecular Genetic Aspects of Idiopathic Myelofibrosis

Cytogenetic and Molecular Genetic Aspects of Idiopathic Myelofibrosis

The Prevalence of Myeloproliferative Disorders in A Group of Iraqi Patients And Its Relation To Blood Indices Parameters

Advances in the Management of Myelofibrosis

Contact Info

Product

Resources

About